The Effects of Efavirenz and Rilpivirine on Lipids and Fat Distribution

In treatment-naive patients, rilpivirine-based ART had modestly less effect than efavirenz-based ART on lipid levels — and similar effects on fat distribution — over 96 weeks of treatment.

Choosing between currently available preferred antiretroviral therapy (ART) regimens often involves issues pertaining to tolerability and long-term effects on metabolic parameters. A recent industry-supported analysis focused on fasting lipid levels (n=1368 patients) and fat distribution (n=413) among participants in the ECHO and THRIVE trials at 96 weeks. These ART-naive patients were receiving either rilpivirine or efavirenz, each plus two nucleoside reverse transcriptase inhibitors (tenofovir and emtricitabine in ECHO; a choice of dual NRTI regimens in THRIVE; NEJM JW AIDS Clin Care Aug 1 2011).

Rilpivirine was associated with significantly smaller changes in lipid levels (total cholesterol, LDL, HDL, and triglycerides) than efavirenz, al…

Reviewing Author

Keith Henry, MD

Disclosures

Consultant/Advisory BoardViiV Advisory Board

Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes

Keith Henry, MD

Disclosures

Consultant/Advisory BoardViiV Advisory Board

Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes

The Effects of Efavirenz and Rilpivirine on Lipids and Fat Distribution

Topics

Reviewing Author